Printed From BioPortfolio.com
Sanofi to develop Principia’s MS drug candidate in $805m deal
01:06 EST 10 Nov 2017 | Pharmaceutical Business Review
Sanofi has agreed to develop Principia Biopharma’s Bruton’s tyrosine kinase (BTK) inhibitor (PRN2246) for the treatment of multiple sclerosis (MS) and possibly other central nervous system (CNS) diseases.
Original Article: Sanofi to develop Principia’s MS drug candidate in $805m deal
